What is the price target for ACOR stock?
7 analysts have analysed ACOR and the average price target is 10.2 USD. This implies a price increase of 1443.12% is expected in the next year compared to the current price of 0.661.
ACORDA THERAPEUTICS INC (ACOR) Forecast, Price Target & Analyst Ratings
NASDAQ:ACOR • US00484M7002
Current stock price
0.661 USD
-0.22 (-24.86%)
At close:
0.5656 USD
-0.1 (-14.43%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ACORDA THERAPEUTICS INC (ACOR).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
$10.20
Upside
+ 1,443.12%
From current price of $0.66 to mean target of $10.20, Based on 7 analyst forecasts
Low
$10.10
Median
$10.20
High
$10.50
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for ACOR. The average price target is 10.2 USD. This implies a price increase of 1443.12% is expected in the next year compared to the current price of 0.661.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
ACOR was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ACOR.
In the previous month the buy percentage consensus was at a similar level.
ACOR was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-06-17 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 2, 2024
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | ||
|---|---|---|---|---|
| Revenue YoY % growth | 129.1M -15.62% | 118.6M -8.13% | 117.633M -0.82% | |
| EBITDA YoY % growth | -39M -254.76% | -2.2M 94.36% | 18.036M 919.82% | |
| EBIT YoY % growth | -73M -353.42% | -35M 52.05% | -13.63M 61.06% | |
| Operating Margin | -56.55% | -29.51% | -11.59% | |
| EPS YoY % growth | -6.43 28.87% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ACORDA THERAPEUTICS INC / ACOR Forecast FAQ
What is the next earnings date for ACOR stock?
ACORDA THERAPEUTICS INC (ACOR) will report earnings on 2024-05-02, after the market close.
Can you provide the analyst count for ACORDA THERAPEUTICS INC stock?
The number of analysts covering ACORDA THERAPEUTICS INC (ACOR) is 7.